Are Recommended Doses of Acetaminophen Effective for Children Aged 2 to 3 Years? A Pharmacokinetic Modeling Answer

Daniel Asher Abourbih1, Sophie Gosselin, Eric Villeneuve

  • 1From the *Division of Emergency Medicine, University of Toronto, Toronto, ON; †Department of Medicine, McGill University, McGill University Health Center; ‡Emergency Department, Montreal General Hospital, §Pharmacy Department, McGill University Health Center, Montréal, QC; and ||Department of Emergency Medicine and Toxicology, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada.

Pediatric Emergency Care
|January 1, 2016
PubMed

Insights

Pediatric acetaminophen (APAP) dosing errors are common. This study found that the 10 mg/kg dose is often insufficient for fever reduction, and the manufacturer

Area of Science:

  • Pharmacology and Pharmaceutical Sciences
  • Pediatric Medicine
  • Mathematical Modeling in Health Sciences

Background:

  • Acetaminophen (APAP) elixir is a common pediatric fever reducer.
  • Inadequate dosing by parents, often due to age-based recommendations, is prevalent.
  • Weight-based dosing guides are proposed, but require pharmacokinetic validation.

Purpose of the Study:

  • To validate recommended acetaminophen (APAP) dosages for children using a pharmacokinetic model.
  • To predict plasma concentrations of APAP to assess efficacy for antipyresis.
  • To compare model-predicted concentrations with the therapeutic range of 10-20 μg/mL.

Main Methods:

  • A mathematical model simulating APAP absorption was employed.
  • The study focused on children aged 2-3 years (10.9-15.9 kg).
  • Manufacturer's 160 mg dose and standard 10-15 mg/kg doses were evaluated.

Main Results:

  • The 10 mg/kg dose predicted peak plasma concentrations below the therapeutic range.
  • The 15 mg/kg dose was adequate only with enhanced absorption assumptions.
  • The 160 mg manufacturer dose was effective only for children at the lower end of the weight range (10.9 kg).

Conclusions:

  • Current 10 mg/kg APAP dosing may be insufficient for pediatric antipyresis.
  • The 160 mg dose is only effective for smaller children, highlighting issues with age-based dosing.
  • Weight-based dosing is crucial, and manufacturers should re-evaluate pediatric APAP recommendations.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
702
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
461
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
372
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
449
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
372